Merck Sharp + Dohme Corp.

Merck + Co., Inc.

Msd R&d Co., Ltd.

Jane Yang Wu

Dongfang Meng

Craig A Stump

Ping Liu

Chun Sing Li

Harold B Wood

Helen Y Chen

Zhiqi Qi

Seongkon Kim

Frank P DiNinno

Yi Heng Chen

Mark E Fraley

Casey Cameron McComas

Jianming Bao

Shawn P Walsh

Helen J Mitchell

Manuel De Lera Ruiz

Richard Berger

Timothy A Blizzard

Yi-Heng Chen

Kerim Babaoglu

Andrew John Cooke

Jiayi Xu

Sookhee Nicole Ha

Timothy Allen Blizzard

Hong Li

Dann LeRoy Parker, Jr

Ting Zhang

Robert Kevin Orr

Qinghua Mao

Nelo R Rivera

Melody McWherter

Bart Harper

Xu-Fang Zhang

Meng Yang

Tianying Jian

Swati P Mercer

Jason Eugene Imbriglio

Ian Mangion

Jeffrey Donald Hermes

Kathy Schirripa

Louis-Charles Campeau

Candido Gude

Sunita V Dewnani

Michael Shevlin

Rebecca T Ruck

Christopher J Mortko

Andrew J Cooke

Melody Mcwherter

Casey C Mccomas

The present invention is directed to bicyclic heteroaryl benzamide compounds of formulas (I): which are tropomyos-in-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.

TrkA kinase inhibitors, compositions and methods thereof

The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, ocular build up of fibrin, and reocclusion or restenosis of recanalized vessels. The compounds are selective Factor IXa inhibitors. 

Factor IXa inhibitors

The present invention is directed to six membered heteroaryl benzamide compounds of formula (I), which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA. 

Substituted bicyclic beta-lactams of Formula I: (I), are &#x3b2;-lactamase inhibitors, wherein a, X, Rand Rare defined herein. The compounds and pharmaceutically acceptable salts thereof are useful in the treatment of bacterial infections in combination with &#x3b2;-lactam antibiotics. In particular, the compounds can be employed with a &#x3b2;-lactam antibiotics (e.g., imipenem, piperacillin, or ceftazidime) against microorganisms resistant to &#x3b2;-lactam antibiotics due to the presence of the &#x3b2;-lactamases.

&#x3b2;-lactamase inhibitors

The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, and cancer, in particular of the breast, uterus and prostate.

Estrogen receptor modulators

Growing community of inventors

Marlboro, NJ, United States of America

Jane Yang Wu